

5th EDITION

Manual of Veterinary Transfusion Medicine

Principles, Techniques and Clinical Applications

HOW CAN I ORDER?

1. CREATE AN ACCOUNT

Go to our website, click in VETS and then in ORDERS; fill in the clinic's details after press REGISTER.

2. INFORMATION EMAIL

You will receive a detailed email explaining how the BSA works, shipping methods and terms & conditions of our services.

3. MAKE YOUR ORDER ONLINE THROUGH THE RESERVED AREA

After accessing the Reserved Area, click on ORDERS.

4. SENDING UNITS FOR TRANSFUSION

Urgent dispatch of the units by the fastest available means of transport.

INDEX

OUR MISSION, VISION, AND VALUES	3
BSA HAS GROWN	6
ANIMAL BLOOD BANK	7—9
BSA GROUP	10
DONORS GALLARY	11
PACKED RED BLOOD CELLS	14—18
FRESH FROZEN PLASMA	22—25
PLATELET CONCENTRATE	27—29
CRYOPRECIPITATE	31—32
CRYOSUPERNATANT	34—35
PLATELET GEL	37—39
TRANSFUSION FORM	43
TRANSFUSION REACTIONS	44—48
TRANSFUSION THERAPY BEST CHOICE	49
TRANSFUSION NEED SCALE FOR PACKED RED BLOOD CELLS	50—52
BIBLIOGRAPHY	55—57



Mission

We are committed to providing high-quality blood components that support veterinary practice with transfusion solutions meeting the highest technical and scientific standards, based on best human medicine practices. We follow international protocols and guidelines, ensuring the safety and effectiveness of treatments for animals.

We also serve as a strategic platform connecting donor animals to critically ill patients in veterinary clinics and hospitals, ensuring the availability of blood transfusions when needed with a high standard of reliability and precision.

Vision

Our goal is to continue to be recognized as the leading institution in veterinary transfusion medicine, both nationally and internationally. We aim to pioneer the development of new blood components and transfusion methods, enhancing the quality and effectiveness of veterinary hemotherapy. We strive to set new standards of excellence through continuous innovation and cutting-edge scientific research.

Values

BSA is dedicated to animal/donor welfare, maintaining an unparalleled reputation for credibility, trust, and integrity. We aim to be a respected animal health institution, grounded in unmatched quality and transparency, without compromising our ethical and professional principles.

BSA has Grown!

Meet our largest ever team of experts!

Use each Country's QR code

TEAM BENELUX



TEAM PORTUGAL



TEAM SPAIN



TEAM UK





COMMITMENTS

We are committed to ensuring the safety and quality of transfusions, offering blood components free from infectious agents and with maximum effectiveness. We strive to deliver the best medical care, ensuring all processes meet the highest standards of quality and safety.

We continuously optimize resources, strengthening our position as a sector leader and ensuring our services are widely recognized by veterinarians and pet owners. We foster ongoing professional development, applying the latest scientific discoveries and technological innovations to our protocols, maintaining leadership in veterinary transfusion medicine.

All our activities are driven by continuous improvement, focusing on customer satisfaction and excellence in care.

The BSA Group upholds its mission, inspected by VMD (UK) and DGAV, advances its vision, and guarantees its values and commitments by:

Implementing and maintaining a Quality Management System aligned with NP ENISO 9001, ensuring compliance with international standards.

Strict adherence to all NP EN ISO 9001 requirements, legal obligations, and applicable good manufacturing practices.

Complying with Good Manufacturing Practices for Veterinary Medicinal Products, as outlined in Ordinance No. 1048/2008, ensuring the safety and effectiveness of the products provided.

OUR POLICY

The BSA GROUP accomplishes their Mission, pursues their Vision, guarantees their Values, and fulfils their Commitments, ensuring the below:

- The implementation and maintenance of a Quality Management System, in accordance with the NP EN ISO 9001 Standard;
- Compliance with the requirements of NP EN ISO 9001 in addition to the appropriate legal obligations and other principles and necessities of good manufacturing practice;
- Compliance with Good Manufacturing Practices for Veterinary Medicines, according to Ordinance No. 1048/2008.

CERTIFICATES & LICENSES

Our personal, equipment, facilities, protocols and animal welfare concerns have been recognised or certified by institutions of excellence:

- General Directorate of Food and Veterinary Medicine (Portugal) Authorisation for Animal Blood Bank
- Veterinary Medicines Directorate Authorisation for Animal Blood Bank
 United Kingdom
- International Society of Feline Medicine Cat Friendly Clinic

QUALITY ASSURANCE

- Quality System certified by Bureau Veritas: an extremely demanding certification, which allows, among other things: protocol control, strict management of suppliers and customers, and unprecedented product traceability.
- Animal Welfare Cat Friendly Clinic Bronze certificate Commitment to animal welfare is of paramount importance. Our donors are an example of kindness and altruism. Their well – being has always been the highest priority of our team and is safeguarded by the implementation of protocols carefully reviewed and scrutinised by the International Society of Feline Medicine. The Cat Friendly certification is a great example of our commitment, confirming that our team, rooms, equipment, and processes are developed to provide the best care to our donors and guarantee their well–being during donations.
- Donor selection all BSA donors are selflessly and independently enrolled by their owners. BSA guarantees the vaccination and parasiticide treat – ment (endo– and ectoparasites), in addition to performing regular blood tests – complete blood count, biochemical analysis and infectious agent screening.
- PCR & serology screening for each unit full analysis system to test for infectious agents in every blood unit donated (all these results are availa – ble and fully accessible to owners or vets via the online 'Reserved Area'):
 - PCR for Ehrlichia spp, Anaplasma spp, Babesia spp, Leishmania spp and Brucella canis (dog)
 - PCR for FeLV provirus, Mycoplasma haemofelis, Candidatus Mycoplasma haemominutum, Candidatus Mycoplasma turicencis and Bartonella spp. (cat)
 - Serology for Ehrlichia spp, Leishmania spp and Dirofilaria immitis (dog)
 FeLV and FIV serology (cat).
- Leukodepletion filtration in every canine unit prevents the production of prothrombotic microparticles and inflammatory cytokines during storage, reducing the haemolysis of the unit, preventing the transmission of

Our donor selection and blood collection protocols have been validated through 2 major scientific studies on the adverse effects after 4439 canine and 3690 feline donations in our blood bank.

- Taylor SS, Ferreira HCM, Cambra AFP, Lo Iacono G, Jeevaratnam K, Mesa-Sanchez I, Ferreira RRF. Feline blood donation: Description and adverse reactions from 29-201 donation events between 2019 and 2023. J Vet Intern Med. 2024 Oct 12.
- Ferreira HCM, Ferreira RRF, Pinto SCP, Mesa-Sanchez I. Prevalence and characteristics of adverse reactions in dogs donating blood. J Small Anim Pract. 2025 Apr 2. doi: 10.1111/jsap.13861.

infectious diseases carried by leukocytes (e.g. Leishmania), reducing the inflammatory response in the recipient and thus the risk of transfusion reactions, and it also increases the shelf–life of stored erythrocytes.

- Blood typing of donors.
- Use of closed systems of blood extraction in dogs and cats that guarantee the sterility of the unit.
- Strict cleaning and sterility procedures during collection, processing, and storage process, to ensure a closed collection system is maintained.
- Quality control of processed units by carrying out bacterial blood cultures, analysis of packed cell volume, haemoglobin concentration and percentage of haemolysis.
- Deep freezing of plasma units, cryoprecipitate and platelet gel (-80°C), ensuring the therapeutic properties of stored proteins.
- Temperature control during transport and storage.
- Procedures established according to the standards and requirements of the European Council for Human Blood Banks.
- Informatic systems that integrates donors, owners, units, analysis, and clinic data, allowing an adequate control of the traceability of any haemocomponent unit.

BSANIMAL APP

The BSA have a free App for iPhone and Android devices. To help the transfusion process, we have developed an App where you can place orders, confirm protocols, volumes and administration speeds for each blood component, or discover the most common transfusion reactions. It also allows access to a Haemocalculator, which automatically calculates volumes and administration rates, according to the patient's species and weight.

RESERVED AREA AT BSANIMAL WEBSITE

The Animal Blood Bank provides an online management system specifically designed to control every unit requested, in stock and consumed. Here you can place orders, consult previous orders, invoices, donor analysis, quality controls, prices and scientific documents or transfusion protocols. Additionally, it is possible to use an internal stock system that allows the management of transfused, expired, or active units in stock. To log in you will need specific credentials provided by the Animal Blood Bank.

Visit us at bsanimal.com | .co.uk | .es | .be | .eu

Our BSA infectious agent detection results have been published in these 2 recent scientific studies. Transfusion transmissible pathogens are prevalent in healthy cats eligible to become blood donors. J Small Anim Pract. 2021 Feb;62(2):107-113. Correia B, Magalhães A, Rocha L, Cardoso I, Ferreira RRF, Mesa-Sanchez I. Prevalence of subclinical infectious agents in a blood donor population tested on every donation. J Small Anim Pract. 2024 Mar;65(3):176-180



OPORTO

Rua de João de Deus, n°741, 4100–462 Porto, Portugal

Rua Dr. Eduardo Santos Silva, 261, fração AH 4200–283 Porto, Portugal

bsa@bsanimal.com +351 221110553 bsanimal.pt

LISBON

Rua Manuel da Fonseca n°7, Loja 6 1600–181 Lisboa, Portugal

bsa@bsanimal.com +351 221110553 bsanimal.pt





BARCELONA

Passatge Rovira I Virgili No 9 Piso 1, 08205 – Sabadell, Spain

+34 935954199 +34 652028817 bsa@bsanimal.es bsanimal.es

LIÉGE

Clinique Vétérinaire Universitaire Batiment B67 Quartier Vallée 2 Avenue de Cureghem, 1, Sart-Tilman, 4000 – Liège, Belgique

- +32 470 95 80 41
- +32 4 366 44 35
- abb@bsanimal.be
- bsanimal.be

WITHOUT THE DONORS, NOTHING WOULD BE POSSIBLE! THANK YOU!





PACKED RED BLOOD CELLS



INDICATIONS

Indicated for the replacement of blood cells that are capable of transporting oxygen to maintain tissue viability. Packed red blood cells should be used primarily in the treatment of symptomatic anaemias (regenerative or non–regenerative):

- Haemolytic anaemias Immune–mediated haemolytic anemia; oxidative damage (intoxication by zinc, paracetamol, onion...); poisoning (snake bite, bee...); microangiopathic hemolysis (e.g. hemangiosarcoma, heartworm, endocarditis, haemolytic–uremic syndrome, splenic torsion); hypophosphatemia (insulin or refeeding syndrome); hereditary erythrocyte enzyme deficiencies (pyruvate kinase or phosphofructokinase deficiency);
- Non-regenerative anemias precursor-targeted IMHA, pure red cell aplasia, myelodysplastic syndrome, myeloproliferation, myelophthisis, myelofibrosis, infection, chronic inflammatory disease, renal disease, or iron deficiency anaemia;
- Surgeries prior correction of anaemia or when large, intraoperative blood loss is expected;
- During cardiopulmonary resuscitation, to allow for increased oxygenation capacity.

IN GENERAL, PRBC TRANSFUSION IS INDICATED IF THE PATIENT PRE-SENTS WITH:

- Clinical signs of hypoperfusion: pale mucous membranes, exercise intolerance, tachycardia, tachypnoea, hypotension;
- Estimated bleeding of >30% of blood volume. In acute haemorrhage, pRBC can be combined with plasma, platelet concentrate, crystalloid or synthetic colloid solutions;
- PCV < 18–21% in dogs with acute presentation anaemia; PCV < 15–18% in chronic presentation anaemia;
- PCV < 25-28% in patients who require anaesthesia;
- Laboratory parameters indicative of hypoperfusion are present: lactate > 4 mmol/L; metabolic acidosis; base excess < -8.

For a more exhaustive assessment of the need for transfusion in dogs and cats, follow the Transfusion Need Scale tables at the end of this manual.

ADVANTAGES OF PRBC OVER WHOLE BLOOD:

Avoids volume overload in patients that do not require plasma proteins. Avoids the risk of immune–mediated reactions to plasma proteins (the major cause of transfusion reactions).

Avoids wasting unnecessary components that can be used in other patients Allows longer storage time for erythrocytes (up to 6 weeks instead of 4 weeks in whole blood).

The benefits of packed red blood cells (pRBC) are temporary, and the primary disease always requires specific treatment.

DID YOU KNOW THAT...

Transfused erythrocytes may improve primary haemostasis? A PCV decrease of 15% increases bleeding time by 60%, regardless of the platelet count.

Increasing PCV corrects bleeding times because erythrocytes stimulate the production of thromboxane and ADP. Besides, the increased erythrocyte mass displaces the platelets to the vessel periphery, increasing interaction with the vascular endothelium.

Recommendations in human medicine: treat patients with anaemia and thrombocytopenia with pRBC to increase PCV over 30–35% before planning platelet transfusion. Transfusion. 2007 Oct;47(4 Suppl):206S-248S.

CONTENTS

Erythrocytes, non-viable platelets, and leukocytes (in cats), and a small volume of plasma.

DOG

Each 220 ml contains approximately:	
Erythrocytes	PCV 55-70%
CPD anticoagulant solution (citrate-phosphate-dextrose)	_10 ml
SAG-M preservative additive solution (saline-adenine-glucose-mannitol)_	70 ml
Plasma	. 10 ml
CAT	
Each 25 ml contains approximately:	
Erythrocytes	PCV 40-55%
CPD anticoagulant solution (citrate-phosphate-dextrose)	1ml
SAG-M preservative additive solution (saline-adenine-glucose-mannitol)_	8 ml
Plasma	2 ml

STORAGE

42 days at 2–6°C. After 28 days always perform an haemolysis test before transfusion.

If the unit is kept at room temperature for more than 15 minutes, it must be
used in the following 6 hours or be refrigerated again and used within 24—
hours. However, a recent study carried out by our team demonstrates that
exposure to room temperature for a longer period does not necessarily
imply a dangerous increase in the percentage of haemolysis or the risk of
bacterial contamination in the unit.

Effects of Room Temperature in Packed Red Blood Cells Units. Abstract presented at the 19th annual European Veterinary Emergency and Critical Care Congress.

- Periodic monitoring of the refrigerator temperature (2–6°C) is advised, with a thermometer or datalogger, and a careful regulation of the thermostat if needed.
- It is recommended to use an exclusive refrigerator for blood products in order to avoid contamination with chemical and biological products, as well as to avoid temperature changes due to frequent door opening.
- Avoid opening the refrigerator frequently, as temperature changes significantly decrease the lifespan of stored erythrocytes.

In BSA, canine pRBC units do not contain leukocytes because we use leukodepletion filters, in order to reduce the risk of transfusion reactions, the risk of transmission of infectious agents and the percentage of haemolysis during storage. The use of leukoreduction filters is essential for the superior quality of these components, following the guidelines of Human Blood Banks.

Leukoreduction effect on the haemolysis of canine packed red blood cells units. Abstract presented in 2020 annual European Veterinary Emergency and Critical Care Annual Congress.

The expiration date of pRBC is an estimation and may change due to several factors related to the donor, collection, shipment, and storage conditions. According to published studies of the BSA, before using units with more than 28 days of storage, it is recommended to value their % of haemolysis, using quantitative or qualitative methods.

In vitro quality control analysis after processing and during storage of feline packed red blood cells units. BMC Vet Res. 2018 14: 141.

In vitro hemolysis of stored units of canine packed red blood cells. J Vet Emerg Crit Care. 2018 Oct:2–6.

VOLUME PER UNIT

Dog: 220 ml (1/2 unit – 100 ml) Cat: 25 ml

Volume may differ 10%

ADMINISTRATION

- Canine pRBC should only be used in dogs and feline pRBC units should only be used in cats.
- The pRBC should not be actively warmed before administration. Allowing 10–15 minutes at room temperature prior to use is recommended because overheating the unit can lead to hemolysis, agglutination, clot formation and bacterial overgrowth.
- The preferred route for pRBC administration is intravenous, preferably with an 20–24 G catheter that should be placed no earlier than 24 hours prior to transfusion; if it is not the case, a new catheter should be placed. In small patients, neonates or with circulatory impairment, the intramedullary route can be used (80–95% of cells are in the circulation after 5 minutes); an 18–20 G needle or a bone marrow aspiration needle should be introduced in the femur trochanteric fossa or the humerus greater tubercle.
- During transfusion, the intravenous catheter should be used exclusively for the administration of blood products. Avoid the concomitant use of intravenous medication, non-isotonic fluids, or lactated Ringer's.
- An administration system with filter must be used. The 170 $\,\mu m$ filters prevent clots, cellular debris, fibrin, and other protein precipitates from entering the vasculature. In general, in small animals (e.g. < 3 kg) it may be advisable to use infusion pumps and transfusion system with 18 μ m paediatric filters, to retain less volume and allow better volume control and administration rate. In animals weighing more than 3 kg, the use of infusion pumps should be avoided whenever possible, considering the possible increased haemolysis induced by the infusion pump.
- The administration of antipyretics, antihistamines or glucocorticoids before the transfusion does not reduce the risk of allergic reaction, febrile non-hemolytic reaction, or other types of transfusion reactions, so their use before the transfusion is generally not recommended.
- The efficacy of the transfusion can be assessed by measuring the PCV immediately after the end of the transfusion (with no significant differences compared to measuring it 4 hours after the end of the transfusion)

TRANSFUSION VOLUME

Basic rule: 10 ml/kg of pRBC increases the PCV by 5-8%.

The desired post–transfusion PCV is the minimum necessary to stabilise the patient and guarantee stable levels of oxygenation (approximately 5–8% higher than the PCV before the transfusion).

INFUSION RATE

For the first 15–30 minutes a slow infusion rate should be used (0,25–0,5 ml/kg/h) to allow for the monitoring of the patient for any transfusion reaction evidence. This slow rate should not be used initially if the recipient is in hypovolemic shock due to acute haemorrhage.

In normovolemic dogs the rate should be 5-10 ml/kg/h for 1-4 hours, and in cats 3-5 ml/kg/h for 2-4 hours.

In animals with hypovolemic shock due to acute haemorrhage, rates up

DID YOU KNOW THAT...

You should avoid the use of infusion pumps?
The administration of erythrocytes through infusion pumps can produce physical damages and has been associated with an increased risk of early elimination of transfused erythrocytes comparing to the administration by gravity.

J Vet Emerg Crit Care (San Antonio). 2011
Jun:21(3):209–16

HOWEVER...

The use of infusion pumps together with in line pediatric filters of 18 µm, could be especially useful in dogs and cats of small size (e.g. <3 kg), allowing better control of the volume and administration rate, without significant increase in haemolysis.

Am J Vet Res. 2019
Sep;80(9):852–861
J Vet Emerg Crit Care
2014;24(2):162–7

A recent study, carried out by our team in cats, showed that the use of linear peristaltic infusion pumps (NIKI V4 [Everest] and Infusomat FmS [B Braun]) does not produce a significant increase in haemolysis. Quantitative assessment of infusion pump—mediated haemolysis in feline packed red blood cell transfusions. J Feline Med Surg. 2021 Dec;23(12):1149—1154

HOW TO CALCULATE INFUSION RATE IN ADMINISTRATION BY GRAVITY?

Use our HEMOCALCULATOR to calculate the number of drops/min. Available in the mobile App BSANIMAL or in the BSA website.

to 20–60 ml/kg/h can be used. However, as arrhythmias due to hypocalcemia may occur, it is advisable to monitor the ECG and serum calcium levels. If higher administration rates are needed, manual compression of the bag or syringe bolus administration may be used, allowing higher rates than by classic infusion methods, without producing significant erythrocyte damage.

In animals at risk of developing volume overload (heart failure, renal failure, hypertension) the infusion rate should be 1–3 ml/kg/h, starting with the slowest rate and gradually increasing it if there are no transfusion reactions signs (e.g. tachypnoea, dyspnoea or jugular vein distension).

In cases of active bleeding due to the deficiency of clotting factors, fresh frozen plasma must also be administered.

PRECAUTIONS / CONTRAINDICATIONS

- Always blood type before the first transfusion in dogs (recommended) and cats (mandatory).
- In dogs, the crossmatching test should be done before the second (and subsequent) transfusion, if more than 3 days have passed since the first transfusion. More detailed information at the end of this chapter.
- Do not simultaneously infuse lactated Ringer's (in the same line). If needed, the safest fluid is 0,9% NaCl. There is no benefit in a simultaneous infusion of crystalloids unless a rapid expansion of the blood volume is needed.
- Use infusion systems with a filter. Do not re–use them for subsequent transfusion.
- Despite blood typing and crossmatching, adverse transfusion reactions may still occur, thus careful monitoring during and after transfusion should be ensured.
- Flush the catheters with 0,9% NaCl solution before and after transfusion.
- Do not administer parenteral medications via the same route used for transfusion.
- Gently mix the contents of each bag for 15 seconds before starting the transfusion.
- Discard any pRBC unit that is damaged, has visible clots, appears discoloured or has a high haemolysis percentage.

DOG

It is recommended to blood type before the first transfusion. In the first transfusion, DEA1 negative units can be used in DEA1 negative or DEA1 positive patients. In case of maximum need, DEA1 positive units can be used in DEA1 negative dogs in the first transfusion, and in the following ones until 3 days after the first transfusion, as there is no risk of acute hemolytic reaction.

CAT

Typing prior to the first transfusion is mandatory and transfused pRBC should be compatible, as acute haemolytic transfusion reactions can be fatal in blood group B recipients.

HAEMOLYSIS EVALUATION

The percentage of haemolysis is an indicator of the viability of stored erythrocytes. If haemolysis is >1% in dogs, or >1,5% in cats, the pRBC unit should not be used. This qualitative method of haemolysis evaluation was developed by BSA and correlates with laboratory quantitative evaluation. The goal is to help clinicians decide whether the pRBC unit should be used or discarded.

This test should perform if the pRBC unit:

- · was stored for more than 28 days
- · cold chain was broken >3 hours
- · presents a strange discoloration

PROTOCOL

- Gently invert the pRBC unit few times over 10 seconds
- Discard the first 10 drops and transfer a sample of the pRBC to a microhematocrit capillary tube (never use the small aliquots attached to the pRBC unit)
- Centrifuge the capillary tube at 5000 rpm for 10 minutes
- Insert the capillary tube into the mobile "reading segment" of this card and, under neutral or natural light, evaluate the colour of the supernatant

10		
9		
8		
7		
6		
5		

Colour 1 – 5 UNIT IS SUITABLE FOR USE Colour 6 – 10 DO NOT USE THE UNIT (haemolysis % > 1% in dogs or >1,5% in cats).

® copyright BSA Group

CROSSMATCHING TEST

These tests help to evaluate the presence of antibodies against additional antigens not detected by the blood typing tests (e.g. Dal, Mik antigen). However, they are not very sensitive to detect antibodies against those blood groups responsible for delayed haemolytic reactions.

Crossmatching can be performed using laboratory tests (agglutination test in a tube or gel column), using commercial rapid tests (gel or immunochromatography) or manually in the clinic.

To perform the manual crossmatching test at the clinic:

- Centrifuge at 3500 rpm (5 minutes) 2 ml of patient blood in EDTA (the same with donor blood if it is not pRBC). Extract and store the plasma in an eppendorf.
- Wash erythrocytes with saline: resuspend 0,25 ml of erythrocytes ml of saline, mix and centrifuge at 3500 rpm for 1 minute. Remosupernatant and repeat this procedure 2 more times. In emergen uations, the erythrocyte washing can be omitted to avoid a delay transfusion.
- Resuspend 0,1–0,2 ml of erythrocytes in 4,8 ml of saline to obtain a solution.
- Perform the following reactions in two microscope slides or eppen-
 - Major crossmatching mix 2 drops of donor's erythrocyte soluti 2 drops of patient's plasma
 - Minor crossmatching mix 2 drops of patient's erythrocyte so with 2 drops of donor's plasma.
- Incubate at 37°C for 20 minutes
- Evaluate the presence of macroscopic or microscopic agglutinal the compatible samples, there should be no haemolysis or agglutin



FRESH FROZEN PLASMA



INDICATIONS

- Plasma protein deficiency including coagulation factors, von Willebrand factor, fibrinogen, albumin, immunoglobulins (passive immunity), antithrombin and protease inhibitors (e.g. α-2-macroglobulin):
- · Volume and clotting factor replacement in massive transfusions;
- Congenital coagulopathies: haemophilia A, haemophilia B, von Willebrand disease, hypofibrinogenemia, etc.
- Acquired coagulopathies: rodenticide poisoning, liver disease, severe cholestasis, DIC or coagulopathy due to acute trauma, hypofibrinogenemia, etc;
- Colloidal support in patients with refractory hypotension or severe hypoalbuminemia;
- Altered vascular permeability and inflammation in critically ill patients with severe SIRS (e.g. sepsis, necrotising pancreatitis, parvovirus, panleukopenia, acute trauma with haemorrhagic shock and blood failure);
- Passive immunity deficiency.

Each 220 ml contains approximately:

CONTENTS

May also contain a small amount of erythrocyte fragments responsible for plasma pigmentation. However, their administration confers no risk to the patient due to the small amount of free haemoglobin.

The benefits of fresh frozen plasma (FFP) are temporary, and the primary disease always requires specific treatment.

NOTE...

Canine FFP preserves the concentration and activity of every coagulation factor of a fresh whole blood unit while maintaining the same therapeutic power.

J Vet Intern Med. 2014
Mar-Apr;28(2):571-5.

Although a decrease in the activity of some coagulation factors (II, VII, VIII, XI and XII) has been observed, feline FFP stored for 1 year between -18°C and -25°C is considered haemostatically active and most coagulation factors coagulation remains within the reference ranges. Stability of coagulation factors on feline fresh frozen plasma after one year of storage. Abstract from the 2020 European Congress of Veterinary Internal Medicine.

DOG

Plasma	180 ml
CPD anticoagulant solution (citrate-phosphate-dextrose)	40 ml
CAT	
Each 25 ml contains approximately:	
Plasma	20 ml
CPD anticoagulant solution (citrate-phosphate-dextrose)	5 ml

DID YOU KNOW THAT...?

Therapy with synthetic colloids in dogs admitted to the intensive care unit, increases the risk of acute renal failure and mortality (dose–dependent). In human medicine, its use is already limited to cases of haemorrhagic hypovolemia during the first 24 hours. J Vet Emerg Crit Care (San Antonio). 2016
Jan–Feb;26(1):35–40

The use of plasma as a natural colloid is an alternative to increase oncotic pressure in hypoalbuminemia or hypotensive cases.

J Vet Emerg Crit Care (San Antonio). 2021

Mar;31(2):263–268.

STORAGE

1 year at temperature ≤ -18°C

After this period, we consider that labile coagulation factors (V and VIII) are lost, and it's relabeled as **FROZEN PLASMA** with an **additional expiry date** of four years at a temperature ≤ -18 °C.

- · Keep bags in an upright position, to easily detect possible thawing.
- Handle frozen bags carefully as they rupture easily. Store in a dedicated freezer to avoid contamination with chemical and biological products.
- It is recommended to place a thermometer or datalogger in the freezer in a central area. Periodic temperature monitoring should be ensured, and the thermostat adjusted as indicated.
- Avoid opening the freezer frequently because temperature fluctuations can shorten the shelf life of this component.
- If you defrost the unit in the refrigerator for a period of less than 24 hours, you can refreeze it; although, the validity is reduced to half the time. If it is defrosted at room temperature, it must not be refrozen and it can be used up to 6 hours after defrosting, or keep the unit refrigerated to be used within 24 hours.

Despite this general idea mentioned by several authors, plasma frozen during 5 years at –30°C appeared to be haemostatically active when evaluated by TEG, with lower the activity of clotting factor VIII and X but not of factor V. J Vet Intern Med. 2013; 27:964–969

After thawing, canine plasma retained over 50% coagulation factor activity for up to 28 days and was considered to have adequate haemostatic potential for transfusion.

J Vet Emerg Crit Care. 2022

Mar;32(2):189–195.

VOLUME PER UNIT

Dog: 220 ml (1/2 unit – 100 ml) Cat: 25 ml Volume may differ 10%

ADMINISTRATION

- Canine plasma should only be used in dogs, and feline plasma should only be used in cats.
- Defrost frozen plasma within a protective plastic bag in a water bath at 30–35°C for 20–30 minutes and stir occasionally; avoid overheating as temperatures over 37°C are responsible for the denaturation of proteins.
 Do not defrost in the microwave due to the risk of overheating or plastic rupture.
- The preferred route of plasma administration is intravenous, preferably with an 20–24 G catheter that should be placed no earlier than 24 hours prior to transfusion; if it is not the case, a new catheter should be placed. In small patients, neonates or with circulatory impairment, the intramedullary route can be used; an 18–20 G needle or a bone marrow aspiration nee dle should be introduced in the femur trochanteric fossa or the humerus greater tubercle.
- During transfusion, the intravenous catheter should be used exclusively for the administration of blood products. Avoid the concomitant use of intravenous medication, non-isotonic fluids, or lactated Ringer's.
- An administration system with filter must be used. The 170 µm filters prevent cellular debris, fibrin clots and other protein precipitates. In general, in small animals (e.g. < 3 kg) it may be advisable to use infusion pumps and transfusion system with 18 µm pediatric filters, to retain less volume and allow better volume control and administration rate.
- · An Infusion pump may be used.
- The administration of antipyretics, antihistamines or glucocorticoids before the transfusion does not reduce the risk of allergic reaction or other types of transfusion reactions, so their use before the transfusion is generally not recommended.

TRANSFUSION VOLUME

Basic rule in hypocoagulation, hypoalbuminemia or decreased passive immunity:

- 10 ml/kg every 6-24 hours in refractory cases as needed
- 20-60 ml/kg in severe cases associated with refractory hypotension

In cases of severe hypoalbuminemia, large volumes of plasma may be necessary to increase albumin.

Up to 10-20 ml/kg may be necessary to increase albumin by 0,2 g/dL.

Goal: improvement of symptoms, haemorrhage control, decrease of clotting times or increase albumin concentration up to 2 g/dl.

INFUSION RATE

For the first 15–30 minutes a slow infusion rate should be used (0,25–0,5 ml/kg/h) to allow for the monitoring of the patient for any evidence of transfusion reaction. This slow rate should not be used initially if the recipient is in hypovolemic shock due to acute haemorrhage.

In normovolemic dogs the rate should be 5–10 ml/kg/h for 2–4 hours, and in cats 3–5 ml/kg/h for 2–4 hours.

In animals at risk of developing volume overload (heart failure, renal failure, hypertension) the infusion rate should be 1–3 ml/kg/h, starting with the slowest rate and gradually increasing it if there are no transfusion reactions signs (e.g. tachypnoea, dyspnoea or jugular vein distension).

PLASMA Constant Rate Infusion (CRI)...

In human medicine, an approximate albumin dose of 0,8 g/kg/day is recommended in critically ill patients with hypoalbuminemia. The mean albumin concentration of canine FFP is approximately 21–25 g/L, thus 32–38 mL/kg of FFP may be required to provide this dose. In hypoalbuminemic patients, plasma can be administered via CRI over 12–24 hours (approximately 1,5–3 ml/kg/h) to achieve increments of 0,3–0,5 g/dL.

Use our HEMOCALCULATOR to calculate doses and rates. Available in the mobile App BSANIMAL or in the BSA website.

ADMINISTRATION TIME...

Use the unit within 4 hours after opening, to minimise the risk of bacterial contamination. However, despite this general indication, a study published recently by our team indicates that transfusion periods of up to 12 hours do not increase the risk of contamination nor significantly change the clotting factor activity or albumin concentration.

Evaluation of canine fresh frozen plasma continuous rate infusion exposed to room temperature for 12 hours: risk of contamination and effects on albumin and coagulation factors. J Vet Emerg Crit Care (San Antonio). 2022; In press.

PRECAUTIONS / CONTRAINDICATIONS

- In dogs, blood typing in plasma administration is not necessary, as it does not reduce the risk of transfusion reaction to plasma proteins.
- In cats, blood typing should always be performed, and the administration of compatible units is mandatory.
- It is not necessary to perform minor crossmatching in dogs, but in theory it is advised in cats.
- Do not simultaneously infuse lactated Ringer's (in the same line). If needed, the safest fluid is 0,9% NaCl. There is no benefit in a simultaneous infusion of crystalloids unless a rapid expansion of the blood volume is needed.
- · Use infusion systems with filter.
- Typing for plasma protein antigens is not possible, meaning there is no way to predict and avoid immune—mediated transfusion reactions.
 Monitoring the animal for these and other reactions like volume overload, is very important during and after transfusion.
- Flush the catheters with 0.9% NaCl solution before and after transfusion.
- Do not administer parenteral medications in the same route used for transfusion.
- Dispose any damaged or perforated unit. The red pigmentation of some plasmas does not constitute a risk because the amount of free haemoglobin in the unit is very low.
- The presence of flakes in suspension or gelatinous clots resulting from the formation of fibrin from fibrinogen is considered normal. This process is enhanced by exposure to temperatures above body temperature.

PLATELET CONCENTRATE



INDICATIONS

Primary haemostatic disorders:

- Severe thrombocytopenias: bone marrow disorders, DIC, neoplasia, immune–mediated or infectious agents (e.g. Ehrlichia, Anaplasma);
- Congenital thrombocytopathies (e.g. Glanzmann's disease) or acquired (e.g. NSAIDs, clopidogrel, uremia, liver failure);
- Prophylaxis in patients with thrombocytopenia or thrombocytopathia submitted to invasive procedures (e.g. biopsy, surgery, endoscopy). Previous transfusion with platelet concentrate (PC) is recommended if < 80 x 10 $^{\circ}$ platelets/ $\mu L.$

Platelet concentrate is not recommended in patients without active bleeding, except as prophylaxis for invasive procedures.

In immune—mediated thrombocytopenia, a rapid destruction of transfused platelets is expected, therefore transfusion with platelets is recommended only in the presence of severe uncontrolled active bleeding.

The benefits of PC are temporary, and the primary disease always requires specific treatment.

CONTENTS

Platelets, leukocytes (non-viable) and plasma.

May also contain a small amount of erythrocyte fragments responsible for platelet units' pigmentation. However, their administration confers no risk to the patient due to the small amount of free haemoglobin.

DOG

FRESHPC

Each 50 ml contains approximately:

Platelets	600.000 - 1.500.000/uL
CPD anticoagulant solution (citrate-phosphate-dextrose)	9 ml
Plasma	40 ml

FROZEN PC

Each 10 ml contains approximately:

Platelets	- 600.000 – 1.500.000/uL
CPD anticoagulant solution (citrate-phosphate-dextrose)	. 1 ml
Plasma	. 8 ml
DMSO cryoprotectant (dimethyl sulfoxide) – toxic in cats	0,5 ml

STORAGE

Fresh PC: 18-24°C, with constant agitation, 7 days.

Frozen PC: ≤ -80°C, 12 months.

VOLUME PER UNIT

Fresh PC: 50 ml.

Frozen PC: 12 ml. Each unit is connected to 30ml unit of FFP, in order to reconstitute the PC before its administration.

Volume may differ 20%

PREPARATION OF FROZEN PC UNIT

- Keep the PC unit and 1/2 unit of FFP within the protective case at room temperature for 20 minutes.
- Carefully handle frozen units because the tube linking the two bags is extremely fragile and can break easily.
- Defrost 1/2 unit of FFP in a water bath (30–35°C), keeping the PC out of the bath. As the volume is very small, the platelet concentrate thaw is very fast at room temperature.
- When both units have thawed, remove both clamps and transfer the FFP to the bag containing the PC.
- · Clamp the tube to avoid reflux.
- Undo the larger lumps (platelet aggregates) that form in the bag to where the FFP has been transferred by massaging gently with a gauze swab.
- When most lumps have disappeared, let the unit rest for 1 hour.
- Massage again to dissolve some of the larger lumps.

ADMINISTRATION

- · The canine PC only must be used in dogs.
- An intravenous 20–22 G catheter should be placed no earlier than 24
 hours prior to transfusion; if it is not the case, a new catheter should be
 placed.
- During transfusion, the intravenous catheter should be used exclusively for the administration of blood products. Avoid the concomitant use of intravenous medication, non-isotonic fluids, or lactated Ringer's.
- An administration system with a filter should be used.
- · Avoid using infusion pumps.
- The administration of antipyretics, antihistamines or glucocorticoids before the transfusion does not reduce the risk of allergic reaction, or other types of transfusion reactions, so their use before the transfusion is generally not recommended.

How to avoid the use of infusion pumps?
Use our HEMOCALCULATOR to calculate doses and rates. Available in the mobile App BSANIMAL or in the BSA website.

TRANSFUSION VOLUME

The volume transfused should be 1 PC unit of 40–70 ml/10 kg SID–TID, until effect. Expected increase of 10–40 x 10^3 platelets/ μ L in each transfusion. This increase in platelets may not be detected by the automatic count, as many of them may be fragmented. However, the haemostatic potential continues to be effective in control of bleeding.

INFUSION RATE

For the first 15–30 minutes a slow infusion rate should be used (0,25–0,5 ml/kg/h) to allow for the monitoring of the patient for any evidence of transfusion reaction. This slow rate should not be used initially if the recipient is in hypovolemic shock due to acute haemorrhage.

Infusion rate should be 5 ml/kg/h in normovolemic dogs.

In dogs at risk of developing volume overload (heart failure, renal failure, hypertension) the infusion rate should be 1–3 ml/kg/h, starting with the slowest rate and gradually increasing it if there are no transfusion reactions signs (e.g. tachypnoea, dyspnoea or jugular vein distension).

PRECAUTIONS / CONTRAINDICATIONS

- Blood typing is not necessary, as it does not reduce the risk of transfusion reaction to platelets or plasma proteins.
- · It is not necessary to perform crossmatching tests.
- For Frozen PC use the unit within the first 3 hours after its preparation.
- Do not simultaneously infuse lactated Ringer's (in the same line). If needed, the safest fluid is 0,9% NaCl.
- Avoid using infusion pumps.
- Use infusion systems with filter.
- Typing for platelets or plasma protein antigens is not possible, meaning there is no way to predict and avoid immune—mediated transfusion reactions. Monitoring the animal for these and other reactions like volume overload, is very important during and after transfusion.
- Sometimes reactions such as tremors, salivation or urticaria can occur caused by a reaction to platelet fragments or substances such as histamine or serotonin. These can be released during the centrifugation process, which may induce inflammatory reactions.
- Flush the catheters with 0,9% NaCl solution before and after transfusion.
- Do not administer parenteral medications in the same route used for transfusion.
- · Dispose any damaged or perforated unit.
- The platelet isolation protocol may lead to the contamination of the PC with a residual number of erythrocytes, being normal a red pigmentation of some units. There is no risk for its administration, as the amount of free haemoglobin is very low.

CRYOPRECIPITATE



INDICATIONS

- Von Willebrand's disease treatment or prevention in invasive procedures;
- Haemophilia A (factor VIII deficiency) treatment or prophylaxis in invasive procedures;
- Hyperfibrinolysis and hypofibrinogenemia (acute trauma, liver disease, DIC, angiostrongylosis...). The goal is to maintain the fibrinogen > 1,5 g/dL.

The benefits of cryoprecipitate are temporary, and the primary disease always requires specific treatment.

ADVANTAGES

Allows for the replenishing of the necessary clotting factors without transfusing large amounts of whole blood or plasma. This reduces the risk of volume overload, or transfusion reactions, and optimises use of blood components.

CONTENTS

Factor VIII, XIII, von Willebrand factor, fibrinogen (10-25 g/L) and fibronectin.

DOG

Each 50 ml contains approximately:	
Cryoprecipitate	45 m
CPD anticoagulant solution (citrate-phosphate-dextrose)	5 ml

STORAGE

1 year at temperature ≤ -18°C

- Keep bags in an upright position, to easily detect possible thawing.
- Handle frozen bags carefully as they rupture easily. Store in a dedicated freezer to avoid contamination with chemical and biological products.
- It is recommended to place a thermometer or datalogger in the freezer in a central area. Periodic temperature monitoring should be ensured, and the thermostat adjusted if needed.
- Avoid opening the freezer frequently because temperature fluctuations can shorten the shelf life of this component.
- If you defrost the unit, it must not be refrozen and it can be used up to 2 hours after defrosting.

VOLUME PER UNIT

45 ml

Volume may differ 10%

ADMINISTRATION

- Canine cryoprecipitate should only be used in dogs.
- Defrost the unit within a protective plastic bag in a water bath at 30–35°C for 20–30 minutes and stir occasionally; avoid overheating as temperatures over 37°C are responsible for the denaturation of proteins. Do not defrost in the microwave due to the risk of overheating or plastic rupture.
- The preferred route of cryoprecipitate administration is intravenous, preferably with an 20–22 G catheter that should be placed no earlier than 24 hours prior to transfusion; if it is not the case, a new catheter should be placed. In small patients, neonates or with circulatory impairment, the intramedullary route can be used; an 18–20 G needle or a bone marrow aspiration needle should be introduced in the femur trochanteric fossa or the humerus greater tubercle.

- During transfusion, the intravenous catheter should be used exclusively for the administration of blood products. Avoid the concomitant use of intravenous medication, non-isotonic fluids, or lactated Ringer's.
- An administration system with filter must be used. The 200 µm filters prevent cellular debris, fibrin clots and other protein precipitates. In general, in small animals (e.g. < 3 kg) it may be advisable to use infusion pumps and transfusion system with 18 µm paediatric filters, to retain less volume and allow better volume control and administration rate.
- · An Infusion pump may be used.
- The administration of antipyretics, antihistamines or glucocorticoids before the transfusion does not reduce the risk of allergic reaction or other types of transfusion reactions, so their use before the transfusion is generally not recommended.

TRANSFUSION VOLUME

4 ml/kg (up to 5 ml/kg, in severe cases) – single dose, SID or BID (depending on the aetiology and coagulation time).

If preventive treatment before surgery is indicated, perform a transfusion in the previous 4 hours. In more invasive surgical procedures, repeat this dose every 30 minutes.

INFUSION RATE

In the first 15–30 minutes, rate should be slow (0,25 ml/kg/h) to evaluate possible transfusion reactions.

As cryoprecipitate has a gelatinous consistence, a slow rate not higher than 2–4 ml/kg/h should be used (depending on the risk of the volume overload). In animals at risk of developing volume overload (heart failure, renal failure, hypertension) a lower infusion rate 1–3 ml/kg/h should be used, starting with the slowest rate, and gradually increasing it if there are no transfusion reactions signs (e.g. tachypnoea, dyspnoea or jugular vein distension).

PRECAUTIONS / CONTRAINDICATIONS

- Blood typing in cryoprecipitate administration is not necessary, as it does not reduce the risk of transfusion reaction to plasma proteins.
- It is not necessary to perform minor crossmatching.
- Do not simultaneously infuse lactated Ringer's (in the same line). If needed, the safest fluid is 0,9% NaCl. There is no benefit in a simultaneous infusion of crystalloids unless a rapid expansion of the blood volume is needed.
- · Use infusion systems with filter.
- Typing for plasma protein antigens is not possible, meaning there is no way
 to predict and avoid immune—mediated transfusion reactions. Monitoring
 the animal for these and other reactions like volume overload, is very important during and after transfusion.
- Flush the catheters with 0.9% NaCl solution before and after transfusion.
- Do not administer parenteral medications in the same route used for transfusion.
- Dispose any damaged or perforated unit. The red pigmentation of some units does not constitute a risk because the amount of free haemoglobin in the unit is very low.
- Gently stir the contents of the cryoprecipitate bag before starting the transfusion.
- · Use the unit within 2 hours after opening.

CRYOSUPERNATANT



INDICATIONS

- This component allows the restoration or increase of albumin levels, passive immunity, thermostable clotting factors (II, V, VII, IX and X) or anti–inflammatory mediators. Cryosupernatant is useful for the same indications as FFP, except von Willbrand's disease, haemophilia A and hyperfibrinolysis or hypofibrinogenemia states. Thus, it can be used in cases of:
- Severe hypoalbuminemia (<1,5 g/dL)
- Rodenticide poisoning
- Vitamin K deficiency
- · Disseminated intravascular coagulation
- · Haemophilia B (factor IX deficit)
- Contribution of passive immunity (deficit of immunoglobulins)

The benefits of CS are temporary, and the primary disease always requires specific treatment.

DID YOU KNOW THAT...?

The administration of cryosupernatant in continuous infusion (average rate 1,8 ml/kg/h; mean transfusion duration of 16 hours) increases the albumin concentration (average increase of 0,6 g/dL). J Vet Emerg Crit Care 2019;29(3):314–20.

CONTENTS

Coagulation factors – Vit–K dependent (II, VII, IX and X) and factors XI, XII; albumin, globulins, anti–inflammatory mediators, antithrombin and protease inhibitors (e.g. α –2–macroglobulin).

May also contain a small amount of erythrocyte fragments responsible for plasma pigmentation. However, their administration confers no risk to the patient due to the small amount of free haemoglobin.

DOG

Each 170 ml contains approximately:	
Cryosupernatant	135ml
CPD anticoagulant solution (citrate-phosphate-dextrose)	35 ml

STORAGE

5 years at temperature < -18°C

- Keep bags in an upright position, to easily detect possible thawing.
- Handle frozen bags carefully as they rupture easily. Store in a dedicated freezer to avoid contamination with chemical and biological products.
- It is recommended to place a thermometer or datalogger in the freezer in a central area. Periodic temperature monitoring should be ensured, and the thermostat adjusted conveniently if needed.
- Avoid opening the freezer frequently because temperature fluctuations can shorten the shelf life of this component.
- If you defrost the unit in the refrigerator for a period of less than 24 hours, you can refreeze it; although, the validity is reduced to half the time. If it is defrosted at room temperature, it must not be refrozen and it can be used up to 6 hours after defrosting, or keep the unit refrigerated to be used within 24 hours.

VOLUME PER UNIT

170 ml

Volume may differ 10%

ADMINISTRATION

The same as for fresh frozen plasma units. Dogs only.

TRANSFUSION VOLUME

Basic rule for hypocoagulation, hypoalbuminemia or decreased passive immunity:

- 10 ml/kg can be repeated every 6-24 hours in refractory cases as needed.
- 20–60 ml/kg in severe cases associated with refractory hypotension
 Up to 10–15 ml/kg may be necessary to increase albumin by 0,2 g/dL.

Goal: improvement of symptoms, haemorrhage control, decrease of clotting times or increase albumin concentration up to 2 g/dl.

A recent study suggests the administration of cryosupernatant in CRI to increase albumin levels and colloid oncotic pressure in critically ill patients. The administration of a mean dose of 31 ml/kg, during a mean infusion time of 16 hours, with a mean administration rate of 1,8 mL/kg/h, allowed a mean albumin increase of 0,6 g/dL. J Vet Emerg Crit Care 2019;29(3):314–20.

INFUSION RATE

The same as for fresh frozen plasma units. Dogs only.

PRECAUTIONS / CONTRAINDICATIONS

The same as for fresh frozen plasma units. Dogs only.

PLATELET GEL



INDICATIONS

Helps the regeneration of hard and soft tissues.

Treatment of external/complex lesions and those that are unresponsive to conventional treatment:

- Burns
- Fistulae (e.g. perianal, oesophagocutaneous)
- · Cleft palate/ cleft lip
- Musculoskeletal lesions (osseous nonunion...)
- · Lesions secondary to neuropathy
- · Lesions secondary to vasculitis.
- Complete reduction of lesion size (margins or depth).
- Partial reduction of the size of the lesion (margins or depth) that allows the surgical procedure.
- · Pain reduction.

Platelet concentrate in local regenerative therapy

- A platelet lysate is obtained after freezing of non-cryopreserved platelet concentrate, promoting rupture of its platelets; this results in dissolved growth factors and platelet cytokines into the extracellular environment ("plasma rich in platelet growth factors").
- Thawed platelet lysate can be activated (by adding calcium salt), promoting the formation of the clot ("platelet gel") in 15–30 minutes, full of growth factors and platelet cytokines.
- Both platelet gel (gel presentation) and platelet lysate (liquid presentation) can be used in regenerative therapy
- Through local application for the treatment of difficult—to—heal cutaneous lesions, joint, tendon, bone or muscle injuries.
- Its high concentration of platelet growth factors could have an effect of chemotaxis on endothelial and mesenchymal cells (e.g. fibroblasts, osteoblasts, chondrocytes, muscle cells or adipocytes), producing greater collagen production, cell proliferation, angiogenesis and restoring microcirculation. This would have an anabolic effect in the injuries, promoting tendons, ligaments, muscles, and cutaneous wounds repair.

CONTENTS

Growth factors such as PDGF (platelet–derived growth factor), TGF– β (transforming growth factor – β), IGF (insulin–like growth factor), FGF (fibroblastic growth factor), EGF (epidermal growth factor), VEGF (vascular endothelial growth factor), NGF (neurotrophic growth factor), HGF (hepatocyte growth factor), and a small volume of plasma.

May also contain a small amount of erythrocyte fragments responsible for plasma pigmentation. However, their administration confers no risk to the patient due to the small amount of free haemoglobin.

DOG

Each 15 ml contains approximately: Platelet lysate

CPD anticoagulant solution (citrate-phosphate-dextrose) 3 ml

Plasma _______ 12 ml

DID YOU KNOW THAT ...?

In a canine study, the topical treatment with platelet gel in chronic wounds decreased the wound diameter by 93% in 1 month, compared to a decrease of only 13% in the control group. Vet Surg. 2014 Aug. ;43(6):726–33.

In orthopaedics, intraarticular platelet concentrate administration in dogs with osteoarthritis, due to cranial cruciate ligament rupture, improves joint function.

PLoS One. 2018 Mar 19;13(3):e0194752.

Platelet concentrate in traumatic bone fractures improves healing.
Int J Mol Sci. 2019 Mar 1;20(5):1075.

The platelet concentrate in local application allows the resolution of prostatic cysts. Can J Vet Res. 2018
Oct;82(4):264–270.

The anticolagenase and epithelializing efficacy of canine platelet lysate is comparable to that of equine serum, thus providing an alternative in the treatment of corneal ulcers with cellular infiltration with or without keratomalacia in these species.

Christophe, et al. XXIII Congress of Veterinary Specialties GTA (2025).

PREPARATION

Platelet gel units are sent as small unit of frozen Platelet Concentrate (PC) and a bottle of 10% calcium gluconate. Calcium gluconate must be added to the PC unit to form a usable gel.

- Remove the unit from the freezer and allow it to thaw in a water bath at 30–35°C for 10 minutes.
- Use a syringe and a needle, add calcium gluconate to the unit through the rubber opening. Add a volume of calcium gluconate that corresponds to 10% of the unit volume.
- Stir gently for 60 seconds and leave it at room temperature or at 37°C.
- In 5–10 minutes, a gel will form, and the bag volume will increase. Gelling times may vary according to the temperature of PC, room temperature and fibrinogen concentration. A small portion of the unit may remain liquid.
- Aseptically cut the bag to remove the gel and apply it over the wound. An
 hydrophobic bandage should be used to cover the gel.
- In a sterile environment, the PC can also be transferred to a sterilised bowl after thawing, by using a syringe and a needle (22G or larger). Add a volume of calcium gluconate that corresponds to 10% of the unit volume.
- The gel should be applied within the first hour after gelling.

STORAGE

2 years at temperature ≤ -80°C

- Handle frozen bags carefully as they rupture easily. Store in a dedicated freezer to avoid contamination with chemical and biological products.
- It is recommended to place a thermometer or datalogger in the freezer in a central area. Periodic temperature monitoring should be ensured, and the thermostat adjusted conveniently if needed.
- Avoid opening the freezer too often as temperature increase will quickly thaw the unit.

VOLUME PER UNIT

15 ml

Volume may differ 20%

APPLICATION

- Platelet gel must be used in dogs.
- Canine platelet gel has been used successfully in feline patients, with no reported adverse reactions. Nevertheless, further research is needed to ensure the safety of this procedure.
- Blood typing is not necessary, as it does not reduce the risk of transfusion reaction to platelets or plasma proteins.
- It is not necessary to perform crossmatching tests.
- Before application, dead tissue should be removed, and the wound borders might need to be surgically reopened for proper effect.
- It should be applied every 3–4 days until wound resolution (usually for 4–8 weeks). This protocol may be adjusted depending on the individual responses and injury characteristics. If there is no response within 3–4 weeks, stop the treatment.

PRECAUTIONS / CONTRAINDICATIONS

- Blood typing is not needed when applying Platelet Gel.
- It should not be applied to infected lesions. These should be treated, and the platelet gel applied only after infection has cleared.
- Do not apply platelet gel in case of neoplasia on the area of the lesion or when there is disseminated neoplasia.
- The effect of the platelet gel application in patients with viremia is unknown and, therefore, unadvised.
- Tissue hypoxia limits the Platelet Gel effect tissue oxygenation should be a major concern.

OUR APP BSANIMAL

SIMPLE TOOL ALWAYS WITH YOU

Transfusion information / Hemocalculator / Place orders / Contacts



ONLINE RESERVED AREA

INTEGRATED DATABASE WITH EVERY INFORMATION

Orders / Invoices / Stock management / Quality controls / Donors analysis / Downloads

NEW SERVICE AUTOMATIC REPLACEMENTS

Just define the minimum and maximum stock - our automatic replacements will ensure the stock everyday





TRANSFUSION FORM

TRANSFUSION FORM

DATE OF TRANSFUSION: RESPONSIBLE:	//S	TART TIM PERI	E::_	STO	OP TIME:	:_	_
PATIENT INFORMATION	.		NOR INFO	ORMATIC		NIIT NIO.	
): REED:		CIES: MPONEN	T.	UI	NIT N°:	
	EX:	BLC	OD TYPE				
BLOOD TYPE:		DOI	NATION D	ATE:	/ /		
WEIGHT: T	RANSFUSION N°	: EXF	PIRATION	DATE:	/ /		
GENERAL ANAESTHESIA?						RFORMED	
					INCOMP	ATIBLE	
DIAGNOSIS/REASON FOR TRA	ANSFUSION:						
TRANSFUSION VOLUME:	ml	VO	LUME INF	USED:_		ml	
PRE-TRANSFUSION PCV:		POS	ST-TRANS	SFUSION	PCV:		_%
	BEFORE	□ 0,5 m	l /Ka/h	_{□5m}	I /Ka/h	□ 10 mL/	Ka/h
	TRANSFUSION		•	□ml			
	0'	15'	30'	1h	2h	3h	4h
BEHAVIOUR							
HEART RATE / PULSE							
RESPIRATORY RATE							
MUCOUS MEMBRANE COLOUR							
TEMPERATURE							
SYSTOLIC BLOOD PRESSURE							
PLASMA COLOUR							
URINE COLOUR							
OBSERVATIONS:		PEF	RFORMED	BY:			
TRANSFUSION REACTION (I	DATE, TIME)						
☐ URTICARIA/PRURITUS/ANG	IOEDEMA		EDEMA_	,	/		
//:	IOLDLIVIA		HEMOSIS	3 /	/ 	<u>·</u>	
□ FEVER / / :		□н	YPOTEN:	SION	/ /	:	
☐ TREMORS/CONVULSIONS	<u> </u>	<u>:</u> _	HOCK_	/ /	:		_
☐ SIALORRHOEA / /	<u> </u>		NURIA	/ /		<u> </u>	
□ VOMITING / /	<u>:</u>					_ :	
DIARRHOEA / /	<u> </u>		ETECHIA			/	:
DYSPNOEA / /	<u>:</u>	⊔P	ULMONA		MBOEM	BOLISM	
COUGH / /		ПС	ARDIAC A		<u>:</u> /	/	

TRANSFUSION REACTIONS

FEBRILE NON-HAEMOLYTIC-REACTIONS

PATHOPHYSIOLOGY AND GENERAL CONSIDERATIONS

- 90% of transfusion reactions.
- Increase in temperature to ≥1°C during transfusion or 4 hours later
- Alloantibodies present in the receptor against plasma proteins and leukocyte or platelet antigens from the donor. Presence of inflammatory cytokines released by leukocytes during storage.
- · More frequent in platelet products or non-leukopleted units.

DIAGNOSIS

- Most likely cause of fever in transfused patients.
- Important to differentiate from acute haemolytic reactions, transfusion-related acute lung injury (TRALI), sepsis secondary to bacterial contamina tion and transmission of infectious diseases.

TREATMENT

- Low clinical relevance.
- Stop the transfusion and later resume it at lower speed once the clinical signs are controlled.
- · Does not require treatment with antipyretics.

CIRCULATORY OVERLOAD ASSOCIATED WITH THE TRANSFUSION

PATHOPHYSIOLOGY AND GENERAL CONSIDERATIONS

- Acute non-immunological reaction secondary to an increase in blood volume.
- Patients at risk: normovolemic anaemias, systemic hypertension, pediatrics, cardiac, respiratory or renal pathology, fast rate or high volume transfusions.
- · Cats are particularly susceptible.

DIAGNOSIS

- Acute respiratory distress and pulmonary oedema within 6 hours after transfusion.
- Dyspnoea, tachypnoea, orthopnoea, cyanosis, coughs, crackles.
- Reduced oxygen saturation or PaO2.
- Radiograph: bilateral pulmonary infiltrate, pleural effusion, perihilar oedema, pulmonary venous congestion, cardiomegaly.
- Echocardiography: left atrial / aorta ratio >2, increased caudal vena cava, hepatic venous congestion, left ventricle dilatation and reduced ejection fraction.
- Increase in NT-proBNP.

TREATMENT

- · Oxygen therapy.
- Furosemide 1–2 mg/kg IV.

TRANSFUSION-RELATED ACUTE LUNG INJURY (TRALI)

PATHOPHYSIOLOGY AND GENERAL CONSIDERATIONS

- · Acute immune reaction.
- Antigen-antibody interaction in the lungs.
- Presence of antibodies in donor plasma against recipient leukocytes.
- Sequestration of neutrophils in the pulmonary endothelium, increased pulmonary vascular permeability, non-cardiogenic oedema and acute respiratory distress syndrome.
- Especially associated with the transfusion of plasma products.
- 6 first hours after the transfusion.

DIAGNOSIS

- Dyspnoea, fever, hypotension, tachycardia and tachypnoea.
- Acute hypoxia (oxygen saturation < 90%)
- Radiograph: pulmonary oedema without evidence of volume overload.
- Echocardiography without volume overload.
- Normal natriuretic peptide.

TREATMENT

- · Oxygen therapy.
- · Mechanical ventilation.
- · Glucocorticoids?.
- · Avoid furosemide.

ALLERGIC REACTIONS

PATHOPHYSIOLOGY AND GENERAL CONSIDERATIONS

- · Acute immune reactions.
- Type I hypersensitivity response (mediated by IgE and mast cells).
- Exposure to donor plasma proteins.
- Especially with plasma and platelet components.
- · 4 first hours of the transfusion.

DIAGNOSIS

- Urticaria, pruritus, erythema, angioedema, bronchoconstriction (especially in cats), vomiting, nausea, diarrhoea and abdominal pain.
- Severe cases: hypotension, syncope, haemoabdomen, coagulopathies and anaphylactic shock

TREATMENT

- · Stop the transfusion and monitor.
- Diphenhydramine 1–2 mg/kg IV or IM.
- Epinephrine 0,1 –0,2 mg/kg IV or IM, followed by CRI at 0,05 –0,1 μg/kg/min IV in severe cases.

ACUTE IMMUNE-MEDIATED HEMOLYTIC REACTION

PATHOPHYSIOLOGY AND GENERAL CONSIDERATIONS

- · Type II hypersensitivity reaction.
- · Incompatibility of erythrocytes between donor and recipient.
- Dogs: After a second incompatible transfusion due to the development of sensitisation antibodies following the first transfusion against the DEA 1, DEA 4 or DAL blood groups.
- Cats: commonly have naturally occurring alloantibodies. Incompatibility
 at the time of first transfusion is therefore possible. Especially serious in
 type B cats that receive type A red cells. Also described in Mik negative
 cats with naturally occurring alloantibodies after a first transfusion with
 positive Mik blood.

DIAGNOSIS

- Fever, tachycardia, hypotension, oliguria / anuria or DIC.
- Inadequate increase in PCV.
- · Haemoglobinemia, haemoglobinuria.
- · Jaundice and increased bilirubin.
- Spherocytes and ghost cells.
- · Positive Coomb's test.

TREATMENT

- · Oxygen therapy if there is hypoperfusion.
- · Glucocorticoids.
- Ensure renal perfusion and adequate blood pressure.
- Possible need for new transfusions.

DELAYED IMMUNE-MEDIATED HAEMOLYTIC REACTION

PATHOPHYSIOLOGY AND GENERAL CONSIDERATIONS

- Secondary immune response against donors erythrocytes.
- Secondary to natural or sensitisation antibodies.
- Dogs: presence of natural antibodies against DEA 3, 5 and 7 blood groups;
 or by sensitisation antibodies 2-5 days after an incompatible transfusion.
- Cats: administration of type B blood to A cats.
- Extravascular haemolysis of transfused erythrocytes (between 24 hours and 28 days afterward).
- Underestimated incidence.

DIAGNOSIS

- Asymptomatic. Some patients experience fever, nausea, vomiting, tachycardia, hypotension or dyspnoea.
- PCV drop between 3 -5 days after transfusion.
- · Jaundice and increased bilirubin.
- Spherocytosis.
- New incompatibilities in crossmatching.

TREATMENT

· Usually not necessary.

NON - IMMUNE-MEDIATED HAEMOLYTIC

PATHOPHYSIOLOGY AND GENERAL CONSIDERATIONS

- · Delayed reaction.
- Due to exposure to high temperatures, prolonged storage, overheating prior to transfusion, administration of non-compatible substances with the pRBC unit (e.g. hypotonic fluids), unit freezing, use of unauthorised infusion pumps, catheters that are too small or bacterial contamination.

DIAGNOSIS

- · Usually asymptomatic.
- · Inadequate PCV increase.
- Some patients show an increase in bilirubin due to extravascular haemolysis.

TREATMENT

· Usually not necessary.

TRANSMISSION OF INFECTIOUS DISEASES

PATHOPHYSIOLOGY AND GENERAL CONSIDERATIONS

- · Acute or delayed non-immunological reaction.
- · Secondary to transfusion with contaminated blood products.
- · Hours or years after the transfusion.

DIAGNOSIS

 Evaluate the presence of (at least): Dogs: Leishmania spp., Ehrlichia spp., Babesia spp., Anaplasma spp. and Brucella spp; Cats: FeLV, FIV, Bartonella spp. and haemotropic Mycoplasmas.

TREATMENT

· Specific treatment for each infectious agent.

BACTERIAL CONTAMINATION

PATHOPHYSIOLOGY AND GENERAL CONSIDERATIONS

 Contamination of the unit with bacteria from the donor's skin during the donation, by donor bacteremia, contamination during the unit's laboratory processing or contamination during the administration.

DIAGNOSIS

- Fever, tachycardia, dyspnoea, vomiting, diarrhoea, hypotension and circulatory collapse.
- · Colour changes or other changes in the pRBC unit.
- · Culture of the patient's and unit's blood.

TREATMENT

 Intravenous antibiotics until you receive the results of the blood culture, then adjust if necessary.

CITRATE TOXICITY

PATHOPHYSIOLOGY AND GENERAL CONSIDERATIONS

- · Acute non-immunological reaction.
- Citrate excess levels in the patient due to massive transfusions or lack of hepatic metabolism (liver failure, hepatic vascular anomalies or paediatric patients).

DIAGNOSIS

- Ptosis, hypersalivation, facial pruritus, hypotension, arrhythmias, vomiting, tetany, muscle tremors or convulsions.
- · Hypocalcemia and hypomagnesemia.

TREATMENT

 Calcium gluconate when ionised Ca is less than 0,9 mmol/L: 4,5-14 mg/kg of elemental calcium IV, slow for 20-30 minutes, diluted if needed; or CRI at 2,5-3,5 mg/kg/h of elemental calcium.

HYPERAMMONEMIA

PATHOPHYSIOLOGY AND GENERAL CONSIDERATIONS

- · Acute non-immunological reaction.
- Ammonia accumulation in the unit during its storage.
- Patients with liver dysfunction (liver failure, portosystemic shunt or newborns with immature functional liver).

DIAGNOSIS

• Mental status alteration, ataxia, head pressing, circling or convulsions.

TREATMENT

· Hepatic encephalopathy treatment.

TRANSFUSION THERAPY BEST CHOICE

	PACKED RED BLOOD CELLS	FRESH FROZEN PLASMA	FROZEN PLASMA / CRYOSUPERNATANT	CRYOPRECIPITATE	COLLOIDS	PLATELET CONCENTRATE
ANAEMIA	•					
ANAEMIA WITH HYPOPROTEINEMIA	•	•	•		•	
HAEMORRHAGIC ANAEMIA (>30% TOTAL BLOOD VOLUME)	•	•			•	
ANAEMIA WITH COAGULOPATHY	•	•				
EVAN'S SYNDROME	•					•
PANCYTOPENIA	•					•
RODENTICIDE POISONING		•	•			
DIC	•	•	•	•		
HAEMOPHILIA A (FACTOR VIII)		•		•		
HAEMOPHILIA B (FACTOR IX)		•	•			
VON WILLEBRAND'S DISEASE		•		•		
WARFARIN POISONING		•	•			
THROMBOCYTOPENIAS/ THROMBOPATHIES						•
HYPOPROTEINEMIA		•	•		•	
PROTHROMBIN DEFICIENCY		•		•		
FIBRINOGEN DEFICIENCY		•		•		
SEPSIS		•	•			
HYPOGLOBULINEMIA (PARVOVIRUS)		•	•			
LIVER DISEASE WITH COAGULOPATHY		•				
LIVER DISEASE WITH ANAEMIA	•	•				
PANCREATITIS		•				
NEONATAL ISOERYTHROLYSIS	•					

- FIRST CHOICE COMPONENT
- ALTERNATIVE COMPONENT

TRANSFUSION NEED SCALE FOR PACKED RED BLOOD CELLS

This Transfusion Need Scale (TNS) aims to offer an integrated protocol that helps to standardise the decision to transfuse packed red blood cells in dogs and cats, providing an efficient tool in routine veterinary practice. After evaluation of the patient, a transfusion final score (TFS) is obtained by adding 3 partial scores (A+B+C) according to these canine and feline protocols.

TRANSFUSION SHOULD BE PERFORMED IF TFS IS \geq 5 AND SHOULD BE AVOIDED IF TNS SCORE < 5.

IMPORTANT: This algorithm is just a guide to help the transfusion decision. It has not yet been evaluated scientifically and should never prevail over the clinical judgement of the veterinarian. Thus, this scale should be seen as a tool to help with the final decision, where the evaluation of the entire clinical case as a whole must always prevail.

CANINE PATIENTS

SCORE A	0	1	2	3
PCV	≥28	25–27	21–24	<21

SCOREB	o	1	2
MUCOUS MEMBRANES COLOR	SALMON PINK	SLIGHTLY PALE	MODERATELY/SEVERELY PALE
CAPIL. REFILL TIME	≤2 SECONDS	_	≥3 SECONDS
PULSE QUALITY	NORMAL	BOUNDING	_
PULSE RATE (PPM)	MEDIUM/GIANT BREEDS 65-109 SMALL BREEDS 80-119	MEDIUM/GIANT BREEDS 110–140 SMALL BREEDS 120–160	MEDIUM/GIANT BREEDS >140 SMALL BREEDS >160
RESPIRATORY RATE (RPM)	15–24	25–40	>40
SAP/ DAP (mmHg)	>100/60	90-100/50-60	<90/<50
MENTATION, EXERCISE TOLERANCE	NORMAL, WALKING	QUIET BUT ABLE TO WALK	LETHARGIC, UNABLE TO WALK
TEMPERATURE	>37°C	_	≤37°C

Score B is determined by the rounded average of the ratings

SCORE C	o	1	2
CARDIOVASCULAR OR RESPIRATORY COMORBIDITIES	NO	YES	
SEVERE ACUTE HAEMORRHAGE	NO	_	YES
RISK OF ISCHAEMIA	NO	YES	
ANAESTHESIA	NO		YES
LACTATE	NORMAL	HIGH	
BASE EXCESS	NORMAL	LOW (< -8)	

Score C is determined by the highest score of the evaluated variables

FELINE PATIENTS

SCORE A	0	1	2	3
PCV	≥24	19–23	16–18	<16

SCORE B	o	1	2
MUCOUS MEMBRANES COLOR	SALMON PINK	SLIGHTLY PALE	MODERATELY/SEVERELY PALE
CAPIL. REFILL TIME	≤2 SECONDS	_	≥3 SECONDS
PULSE QUALITY	NORMAL	BOUNDING	WEAK
PULSE RATE (PPM)	<200	200–220	≥221
RESPIRATORY RATE (RPM)	15–24	25–40	>40
SAP/ DAP (mmHg)	>100 / 60	90-100 / 50-60	<90 / <50
MENTATION, EXERCISE TOLERANCE	NORMAL, WALKING	QUIET	LETHARGIC, UNABLE TO WALK
TEMPERATURE	>38°C	37-38°C	<37°C

Score B is determined by the rounded average of the ratings

SCOREC	0	1	2
CARDIOVASCULAR OR RESPIRATORY COMORBIDITIES	NO	YES	
SEVERE ACUTE HAEMORRHAGE	NO	_	YES
RISK OF ISCHAEMIA	NO	YES	
ANAESTHESIA	NO		YES
LACTATE	NORMAL	HIGH	
BASE EXCESS	NORMAL	LOW (< -8)	

Score C is determined by the highest score of the evaluated variables

BIBLIOGRAPHY



Abrams–Ogg A, Schneider A. (2010) Principles of canine and feline blood collection, processing, and storage In: Weiss DJ, Wardrop KJ, eds. Schalm's Veterinary Hematology. 6th ed. Iowa, USA: Wilev–Blackwell: 731–737.

Abrams–Ogg A. (2003) Triggers for prophylactic use of platelet transfusions and optimal platelet dosing in thrombocytopenic dogs and cats. Vet Clin North Am Small Anim Pract; 33:1401–1418.

Abreu AM, Oliveira AS, Ferreira RF, et al. (2022) Feline blood donation adverse reactions: clas sification and description of acute and delayed reactions in a donor population. J Feline Med Surg. Apr;24(4):284–289.

American association of veterinary blood banks. (2005) Collection and production of components. In: Hale AS, Kaufman P, Ziller M, eds. Standards for blood banks and transfusion services. 1st ed. California. USA: AAVBB: 16–27.

Authement JM, Wolfsheimer KJ. (1987) Catchings S. Canine blood component therapy: Product preparation, storage, and administration. Clin Tech Small Anim Pract; 23:483–493.

Barbara C, Ferreira RF, Mesa Sanchez I, et al. (2022) Prevalence of transmissible canine blood pathogens in a blood donor population tested on every donation. Abstract presented in 2022 annual European Veterinary Emergency and Critical Care Congress.

Blais MC, Rozanski EA, Hale AS, et al. (2009) Lack of evidence of pregnancy-induced alloan-tibodies in dogs. J Vet Intern Med; 23:462–465.

Blasi Brugué C, Ferreira RF, Mesa Sanchez I, et al. (2018) In vitro quality control analysis after processing and during storage of feline packed red blood cells units. BMC Vet Res; 14: 141.

Blasi Brugué C, Ferreira RF, Mesa Sanchez I, et al. (2021) Quantitative assessment of infusion pump-mediated haemolysis in feline packed red blood cell transfusions. J Feline Med Surg. Dec;23(12):1149-1154.

Blasi–Brugué C, Mesa Sanchez I, Ferreira RF, et al. (2020) Stability of coagulation factors on feline fresh frozen plasma after one year of storage. Abstract from the 2020 European Congress of Veterinary Internal Medicine.

Blood transfusions. BSAVA's Scientific Committee. (2000) British Small Animal Veterinary Association. J Small Anim Pract.; 41:431–434.

Bracker KE, Drellich S. (2005) Transfusion reactions. Comp Cont Educ Pract Vet; 27:500-512.

Callan MB, Appleman EH, Sachais BS. (2009) Canine platelet transfusions: state-of-the-art review. J Vet Emerg Crit Care (San Antonio); 19:401-415.

Callan MB. (2010) Red blood cell transfusion in the dog and cat. In: Weiss DJ,Wardrop KJ, eds. Schalm's Veterinary Hematology. 6th ed. Iowa, USA: Wiley–Blackwell; 738–743.

Chee W, Sharp CR, Boyd CJ, et al. (2022) Stability of ex vivo coagulation factor activity in never–frozen and thawed refrigerated canine plasma stored for 42 days. J Vet Emerg Crit Care (San Antonio). Mar;32(2):189–195.

Chiaramonte D. (2004) Blood-component therapy: selection, administration and monitoring. Clin Tech Small Anim Pract: 19:63–67.

Conversy B, Blais MC, Carioto L, et al. (2013) Comparison of gravity collection versus suction collection for transfusion purposes in dogs. J Am Vet Med Assoc; 49:301–307.

Cooley–Lock KM, Williams JP, et al. (2019) Assessment of erythrocyte damage and in–line pressure changes associated with simulated transfusion of canine blood through microaggregate filters. Am J Vet Res. Sep;80(9):852–861.

Council of Europe. (2011) Principles of Component Preparation. In: Guide to the preparation, use and quality assurance of blood components. 16th ed. Strasburg, France: Council of Europe Publishing; 59–81.

Culler CA, Balakrishnan A, et al. (2019) Clinical use of cryopoor plasma continuous rate infusion in critically ill, hypoalbuminemic dogs. J Vet Emerg Crit Care;29(3):314–20.

Davidow B. (2013) Transfusion medicine in small animals. Vet Clin North Am Small Anim Pract; 43:735–756.

D avidow E, et al. (2021) Association of Veterinary Hematology and Transfusion Medicine (AVHTM) Transfusion Reaction Small Animal Consensus Statement (TRACS). Part 1: Definitions and clinical signs. J Vet Emerg Crit Care. 1–26. DOI: 10.1111/vec.13044

D avidow E, et al. (2021) Association of Veterinary Hematology and Transfusion Medicine (AVHTM) Transfusion Reaction Small Animal Consensus Statement (TRACS). Part 2: Prevention and monitoring. J Vet Emerg Crit Care. 1–22. DOI: 10.1111/vec.13045

D avidow E, et al. (2021) Association of Veterinary Hematology and Transfusion Medicine (AVHTM) Transfusion Reaction Small Animal Consensus Statement (TRACS). Part 3: Diagnosis and treatment. J Vet Emerg Crit Care. 1–15. DOI: 10.1111/vec.13043

Elias N, Lewis DH. (2021) Indications for use and complications associated with canine plasma products in 170 patients. J Vet Emerg Crit Care (San Antonio). Mar;31(2):263–268.

Feldman BF, Sink CA. (2008) Clinical considerations in transfusion practice. In: Feldman BF, Sink CA, eds. Practical transfusion medicine for the small animal practitioner. 1st ed. Wyoming, USA: Teton Newmedia; 38–47.

Feldman BF, Sink CA. (2008) Collection, processing, storage and shipment. In: Feldman BF, – Sink CA, eds. Practical transfusion medicine for the small animal practitioner. 1st ed. Wyoming, USA: Teton Newmedia: 15–37.

Ferreira HC, Ferreira RF, Pinto SC, et al. (2022) Canine blood donation adverse reactions: classification and description of reactions in a donor population. Abstract presented in 2022 annual European Veterinary Emergency and Critical Care Congress.

Ferreira RF, Gopegui R, Maia S, et al. (2013) Laboratory analysis of canine packed red blood cells – effects of collection and processing on haemolysis, haemoglobin concentration, haematocrit and blood culture. Comp Clin Pathol. 5(23):1395–1401.

Ferreira RF, Gopegui RR, Matos AJ, et al. (2014) Effects of repeated blood donations on iron status and haematologic variables of canine blood donors. J Am Vet Med Assoc. Jun;244(11):1298–1303.

Ferreira RF, Graça RM, et al. (2018) In vitro hemolysis of stored units of canine packed red blood cells. J Vet Emerg Crit Care. Oct:2–6.

Ferreira RF, Cardoso I, et al. (2019) Effects of Room Temperature in Packed Red Blood Cells Units. Abstract presented in 2019 annual European Veterinary Emergency and Critical Care Congress.

Ferreira RF, Cardoso I; Mesa Sanchez I, et al. (2020) Leukoreduction effect on the haemolysis of canine packed red blood cells units. Abstract presented in 2020 European Veterinary Emergency and Critical Care Annual Congress. https://doi.org/10.1111/vec.12988

Ford RB, Mazzaferro EM. (2006) Emergency care – blood component therapy. In: Ford RB, Mazzaferro EM, eds. Kirk and Bistner's Handbook of veterinary procedures and emergency treatment. 8th ed. Missouri, United States of America: Saunders Elsevier; 21–33.

Gibson G, Abrams–Ogg A. (2012) Canine transfusion medicine. In: Day MJ, Kohn B, eds. Canine and feline haematology and transfusion medicine. 2nd ed. Gloucester, UK: British Small Animal Veterinary Association; 289–307.

Giger U, Blais MC. (2005) Ensuring blood compatibility: update on canine typing and cross-matching. Proceedings of 23th American College of Veterinary Internal Medicine Congress. Baltimore. USA.

Hale AS. (1995) Canine blood groups and their importance in veterinary transfusion medicine. Vet Clin North Am Small Anim Pract; 25:1323–1332.

Harrell KA, Kristensen AT. (1995) Canine transfusion reactions and their management. Vet Clin North Am Small Anim Pract; 25:1333–1364.

Hayes G, Benedicenti L, Mathews K. (2016) Retrospective cohort study on the incidence of acute kidney injury and death following hydroxyethyl starch (HES 10% 250/0.5/5:1) administration in dogs (2007–2010). J Vet Emerg Crit Care (San Antonio); 26(1):35–40.

Heikes BW, Ruaux CG. (2014) Effect of syringe and aggregate filter administration on survival of transfused autologous fresh feline red blood cells. J Vet Emerg Crit Care. 24(2):162–167.

Helm J, Knottenbelt C. (2010) Blood transfusions in dogs and cats 1. Indications. In Practice; 32:184–189.

Helm J, Knottenbelt C. (2010) Blood transfusions in dogs and cats 2. Practicalities of blood collection and administration. In Practice; 32:231–237.

Killingsworth CR. (1984) Use of blood and blood components for feline and canine patients. J Am Vet Med Assoc; 185:1452–1454.

Kisielewicz C, Self IA. (2014) Canine and feline blood transfusions: controversies and recent advances in administration practices. Vet Anaesth Analg; 41(3):233–242.

Knottenbelt C, Mackin A. (1998) Blood transfusions in the dog and cat Part 2: Indications and safe administration. In Practice: 20:191–199.

Kristensen AT, Feldman BF. (1995) General principles of small animal blood component administration. Vet Clin North Am Small Anim Pract; 25:1277–1290.

Lanevschi A, Wardrop KJ. (2001) Principles of transfusion medicine in small animals. Can Vet J: 42:447–454.

Lucas RL, Lentz KD, Hale AS. (2004) Collection and preparation of blood products. Clin Tech Small Anim Pract: 19:55–62.

Mathews KA, Scott H and Abrams—ogg A. (2006) Transfusion of blood products. In: Mathews KA, ed. Veterinary Emergency and Critical Care Manual. 2nd ed. Ontario, Canada: Lifelearn; 667–681.

McDevitt RI, Ruaux CG, Baltzer WI. (2011) Influence of transfusion technique on survival of autologous red blood cells in the dog. J Vet Emerg Crit Care (San Antonio); 21(3):209–216.

Mesa–Sanchez I, Ferreira RF, Blasi–Brugué C, et al. (2022) Evaluation of canine fresh frozen plasma continuous rate infusion exposed to room temperature for 12 hours: risk of contamination and effects on albumin and coagulation factors. J Vet Emerg Crit Care (San Antonio). In press.

Mesa–Sanchez I, Ferreira RF, Cardoso I, et al. (2021) Transfusion transmissible pathogens are prevalent in healthy cats eligible to become blood donors. J Small Anim Pract. 2021 Feb:62(2):107–113.

Pichler ME, Turnwald GH. (1985) Blood transfusion in the dog and cat. Part 1: Physiology, collection, storage and indications for whole blood therapy. Comp Cont Educ Pract Vet; 7:64–70.

Price GS, Armstrong PJ, McLeod DA, et al. (1988) Evaluation of citrate-phosphate-dextrose-adenine as a storage medium for packed canine erythrocytes. J Vet Intern Med; 2:126–132.

Pritte JE. (2003) Triggers for use, optimal dosing, and problems associated with red cell trans fusions. Vet Clin North Am Small Anim Pract; 33:1261–1275.

Pritte JE. (2010) Controversies related to red blood cell transfusion in critically ill patients. J Vet Emerg Crit Care (San Antonio); 20:167–176.

Roberts J, Haldane S, Marks SL, et al. (2004) Transfusion medicine. Compend Contin Educ Vet: 26:502–518.

Schneider A. (1995) Blood components. Collection, processing, and storage. Vet Clin North Am Small Anim Pract: 25:1245–1261.

Short JL, Diehl S, Seshadri R, et al. (2012) Accuracy of formulas used to predict post-transfusion packed cell volume rise in anemic dogs. J Vet Emerg Crit Care (San Antonio): 22:428–434.

Sowemimo–Cocker SO. (2002) Red blood cell hemolysis during processing. Transfus Med Rev; 16:46–60.

Stone E, Badner D, Cotter SM. (1992) Trends in transfusion medicine in dogs at a veterinary school clinic: 315 cases (1986–1989). J Am Vet Med Assoc; 200:1000–1004.

Tocci LJ. (2010) Transfusion medicine in small animal practice. Vet Clin North Am Small Anim Pract; 40:485–494.

Valeri CR, Khuri S, Ragno G et al. (2007) Nonsurgical bleeding diathesis in anemic thrombocytopenic patients: role of temperature, red blood cells, platelets, and plasma–clotting proteins. Transfusion. Oct:47(4 Suppl):206S–248S.

Walton JE, Hale AS, Brooks MB, et al. (2014) Coagulation factor and hemostatic protein content of canine plasma after storage of whole blood at Ambient Temperature. J Vet Intern Med; 28(2):571–575.

Wardrop KJ, Owen TJ, Meyers KM. (1994) Evaluation of an additive solution for preservation of canine red blood cells. J Vet Intern Med; 8:253–257.

Wardrop KJ, Reine N, Birkenheuer A, et al. (2005) Canine and feline blood donor screening for infectious disease. J Vet Intern Med; 19:135–142.

Wardrop KJ, Tucker RL, Mugnai K. (1997) Evaluation of canine red blood cells stored in a saline, adenine, and glucose solution for 35 days. J Vet Intern Med; 11:5–8.

Wardrop KJ. (1995) Selection of anticoagulant–preservatives for canine and feline blood storage. Vet Clin North Am Small Anim Pract; 25:1263–1276.

Wardrop KJ. (2008) Transfusion medicine In: Morgan RV, ed. Handbook of Small Animal Practice. 5th ed. Missouri, USA: Saunders Elsevier; 707–713.

Weiss DJ, Wardrop KJ, eds. Schalm's Veterinary Hematology. 6th ed. Iowa, USA: Wiley–Black-well; 731–737.

Zimmermann R, Heidenreich D, Weisbach V, et al. (2003) In vitro quality control of red blood cell concentrates outdated in clinical practice. Transfus Clin Biol; 10:275–283.

Correia B, Magalhães A, Rocha L, Cardoso I, Ferreira RRF, Mesa-Sanchez I. Prevalence of subclinical infectious agents in a blood donor population tested on every donation. J Small Anim Pract. 2024 Mar;65(3):176-180

The anticolagenase and epithelializing efficacy of canine platelet lysate is comparable to that of equine serum, thus providing an alternative in the treatment of corneal ulcers with cellular infiltration with or without keratomalacia in these species.

Christophe, et al. XXIII Congress of Veterinary Specialties GTA (2025).

Taylor SS, Ferreira HCM, Cambra AFP, Lo Iacono G, Jeevaratnam K, Mesa-Sanchez I, Ferreira RRF. Feline blood donation: Description and adverse reactions from 29 201 donation events between 2019 and 2023. J Vet Intern Med. 2024 Oct 12.

Ferreira HCM, Ferreira RRF, Pinto SCP, Mesa-Sanchez I. Prevalence and characteristics of adverse reactions in dogs donating blood. J Small Anim Pract. 2025 Apr 2. doi: 10.1111/jsap.13861.

Manual of Transfusion Medicine 5th Edition

Ignácio Mesa Sánchez, DVM PhD, Dipl, EVCVIM-CA

We gratefully acknowledge Dr. Rui Ferreira for his significant contributions to the first through fourth editions of this manual.

Fifth Edition, 2025 Animal Blood Bank® All rights reserved. Printed in Portugal

BANCO DE SANGUE ANIMAL

Rua de João de Deus, n°741, 4100–462 Porto, Portugal

Rua Manuel da Fonseca nº7, Loja 6 1600–181 Lisboa, Portugal

bsa@bsanimal.com +351 221110553 bsanimal.com

BANCO DE SANGRE ANIMAL

Passatge Rovira I Virgili No 9 Piso 1, 08205 – Sabadell, Spain

+34 935954199

+34 652028817

bsa@bsanimal.es

bsanimal.es

ANIMAL BLOOD BANK BENELUX

Clinique Vétérinaire Universitaire Batiment B67 Quartier Vallée 2 Avenue de Cureghem, 1, Sart-Tilman, 4000 – Liège, Belgique

+32 470 95 80 41

+32 4 366 44 35

abb@bsanimal.be

bsanimal.be

ANIMAL BLOOD BANK UK

C/O Brodies LLP 58 Morrison Street Edinburgh EH3 8BP, United Kingdom

+351 221 110 553 bsa@bsanimal.co.uk uk.animalbb.org





ANIMAL BLOOD BANK